Stull, Stull & Brody Announces Class Action Suit on Behalf of Purchasers of Common Shares of Northwest Biotherapeutics, Inc. — NWBO

[GlobeNewswire] – NEW YORK, Sept. 04, 2015– Stull, Stull& Brody announces that a class action lawsuit was commenced in the United States District Court for the District of Maryland on behalf of perso…Read More »

Law Offices of Marc S. Henzel Announces Securities Class Action Periods

[PR Newswire] – MERION, Pa., Sept. 3, 2015 /PRNewswire/ — The Law Offices of Marc S. Henzel ( www.henzellaw.com ), a firm focusing on shareholder litigation, gives notice to purchasers of the followi…Read More »

SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in Northwest Biotherapeutics, Inc. to Contact Brower Piven Before the Lead Plaintiff Deadline in Class Action Lawsuit – NWBO

[GlobeNewswire] – STEVENSON, Md., Sept. 02, 2015– The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the Unite…Read More »

Northwest Biotherapeutics, Inc. Shareholder Alert: Former SEC Attorney Willie Briscoe and Powers Taylor Investigate Possible Breaches of Fiduciary Duty by Officers and Directors

[Business Wire] – Former United States Securities and Exchange Commission attorney Willie Briscoe, founder of The Briscoe Law Firm, PLLC, and the securities litigation firm of Powers Taylor LLP announ…Read More »

EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Northwest Biotherapeutics, Inc. – NWBO

[Business Wire] – Rosen Law Firm, a global investor rights law firm, announces that a class action lawsuit has been filed on behalf of purchasers of Northwest Biotherapeutics, Inc. securities from Mar…Read More »

Forward Looking Statements

Statements made in this news release that are not historical facts, including statements concerning future treatment of patients using DCVax and future clinical trials, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “expect,” “believe,” “intend,” “design,” “plan,” “continue,” “may,” “will,” “anticipate,” and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as risks related to the use of proceeds; the exercise of the Overallotment Right and the satisfaction of customary closing conditions for such exercise; the Company’s ability to raise additional capital, risks related to the Company’s ability to enroll patients in its clinical trials and complete the trials on a timely basis, uncertainties about the clinical trials process, uncertainties about the timely performance of third parties, risks related to whether the Company’s products will demonstrate safety and efficacy, risks related to the Company’s and Cognate’s abilities to carry out the intended manufacturing expansions contemplated in the Cognate Agreements, risks related to the Company’s ability to carry out the Hospital Exemption program and risks related to possible reimbursement and pricing. Additional information on these and other factors, including Risk Factors, which could affect the Company’s results, is included in its Securities and Exchange Commission (“SEC”) filings. Finally, there may be other factors not mentioned above or included in the Company’s SEC filings that may cause actual results to differ materially from those projected in any forward-looking statement. You should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.

This Blog is official and sanctioned by Northwest Biotherapeutics | See Disclaimer | See Privacy Policy

Get Northwest Biotherapeutics Blog Post Alerts